Dermatologist Preferences for First-Line Therapy of Moderate-to-Severe Psoriasis in Healthy Adults

被引：0
|
作者：
Wan, Joy [1 ]
Abuabara, Katrina [1 ]
Troxel, Andrea B. [1 ]
Shin, Daniel B. [1 ]
Van Voorhees, Abby S. [1 ]
Bebo, Bruce F., Jr. [2 ]
Krueger, Gerald G. [3 ]
Duffin, Kristina Callis [3 ]
Gelfand, Joel M. [1 ]
机构：
[1] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[2] Natl Psoriasis Fdn, Portland, OR USA
[3] Univ Utah, Sch Med, Salt Lake City, UT USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2011年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
261
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [1] Dermatologist preferences for first-line therapy of moderate-to-severe psoriasis in healthy adults
    Wan, J.
    Abuabara, K.
    Troxel, A. B.
    Shin, D. B.
    Van Voorhees, A. S.
    Bebo, B. F.
    Krueger, G. G.
    Duffin, K. Callis
    Geliand, J. M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 : S35 - S35
  • [2] Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients
    Wan, Joy
    Abuabara, Katrina
    Troxel, Andrea B.
    Shin, Daniel B.
    Van Voorhees, Abby S.
    Bebo, Bruce F., Jr.
    Krueger, Gerald G.
    Duffin, Kristina Callis
    Gelfand, Joel M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (03) : 376 - 386
  • [3] First line biologic agent therapy for moderate-to-severe psoriasis in cancer survivors
    Majewksi, Sara
    Kheterpal, Meenal
    Nardone, Beatrice
    Sable, Kimberly
    West, Dennis P.
    Lacouture, Mario E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB250 - AB250
  • [4] First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq
    Assan, Florence
    Tubach, Florence
    Arlegui, Hugo
    Viguier, Manuelle
    Beylot-Barry, Marie
    Dupuy, Alain
    Beneton, Nathalie
    Joly, Pascal
    Jullien, Denis
    Mahe, Emmanuel
    Paul, Carle
    Richard, Marie-Aleth
    Bachelez, Herve
    Giboin, Caroline
    Chosidow, Olivier
    Sbidian, Emilie
    DERMATOLOGY, 2021, 237 (03) : 338 - 346
  • [5] Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
    Mina Amin
    Daniel J. No
    Alexander Egeberg
    Jashin J. Wu
    American Journal of Clinical Dermatology, 2018, 19 : 1 - 13
  • [6] Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
    Amin, Mina
    No, Daniel J.
    Egeberg, Alexander
    Wu, Jashin J.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (01) : 1 - 13
  • [7] Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis
    Matthew Alcusky
    Seina Lee
    Gordon Lau
    Gretchen R. Chiu
    Nandini Hadker
    Aparna Deshpande
    Stephen Fleming
    Nicola Vance
    Steve Fakharzadeh
    Dermatology and Therapy, 2017, 7 : 463 - 483
  • [8] Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis
    Alcusky, Matthew
    Lee, Seina
    Lau, Gordon
    Chiu, Gretchen R.
    Hadker, Nandini
    Deshpande, Aparna
    Fleming, Stephen
    Vance, Nicola
    Fakharzadeh, Steve
    DERMATOLOGY AND THERAPY, 2017, 7 (04) : 463 - 483
  • [9] GRAPPA Debate: Targeted Small Molecules Versus Biologics as First-Line Systemic Therapy After Conventional Therapy for Moderate-to-Severe Psoriasis
    Liao, Wilson
    Armstrong, April W.
    Duffin, Kristina Callis
    JOURNAL OF RHEUMATOLOGY, 2024, 51 : 89 - 92
  • [10] Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment or moderate-to-severe psoriasis in the UK
    Johansson, Erin Colleen
    Hartz, Susanne
    Kiri, Sandeep Himatlal
    Kumar, Gayathri
    Svedbom, Axel
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) : 810 - 820
12345